382 related articles for article (PubMed ID: 28675164)
1. Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells.
Gan HK; van den Bent M; Lassman AB; Reardon DA; Scott AM
Nat Rev Clin Oncol; 2017 Nov; 14(11):695-707. PubMed ID: 28675164
[TBL] [Abstract][Full Text] [Related]
2. Toxic warhead-armed antibody for targeted treatment of glioblastoma.
Xi J; Liu K; Peng Z; Dai X; Wang Y; Cai C; Yang D; Yan C; Li X
Crit Rev Oncol Hematol; 2024 Jan; 193():104205. PubMed ID: 38036153
[TBL] [Abstract][Full Text] [Related]
3. Antibody drug conjugates for glioblastoma: current progress towards clinical use.
Gan HK; Parakh S; Osellame LD; Cher L; Uccellini A; Hafeez U; Menon S; Scott AM
Expert Opin Biol Ther; 2023; 23(11):1089-1102. PubMed ID: 37955063
[TBL] [Abstract][Full Text] [Related]
4. Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours.
Mair MJ; Bartsch R; Le Rhun E; Berghoff AS; Brastianos PK; Cortes J; Gan HK; Lin NU; Lassman AB; Wen PY; Weller M; van den Bent M; Preusser M
Nat Rev Clin Oncol; 2023 Jun; 20(6):372-389. PubMed ID: 37085569
[TBL] [Abstract][Full Text] [Related]
5. [Epidermic growth factor receptor (EGFR) in glioblastomas: the mechanism of tumorigenesis and its role as a therapeutic target].
Zahonero C; Sepúlveda JM; Sánchez-Gómez P
Rev Neurol; 2015 Jul; 61(2):85-93. PubMed ID: 26156444
[TBL] [Abstract][Full Text] [Related]
6. Molecular targets in glioblastoma.
Zorzan M; Giordan E; Redaelli M; Caretta A; Mucignat-Caretta C
Future Oncol; 2015; 11(9):1407-20. PubMed ID: 25952786
[TBL] [Abstract][Full Text] [Related]
7. [New therapeutic approaches in glioblastomas].
Carpentier AF
Bull Cancer; 2005 Apr; 92(4):355-9. PubMed ID: 15888392
[TBL] [Abstract][Full Text] [Related]
8. Toward precision medicine in glioblastoma: the promise and the challenges.
Prados MD; Byron SA; Tran NL; Phillips JJ; Molinaro AM; Ligon KL; Wen PY; Kuhn JG; Mellinghoff IK; de Groot JF; Colman H; Cloughesy TF; Chang SM; Ryken TC; Tembe WD; Kiefer JA; Berens ME; Craig DW; Carpten JD; Trent JM
Neuro Oncol; 2015 Aug; 17(8):1051-63. PubMed ID: 25934816
[TBL] [Abstract][Full Text] [Related]
9. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours.
Halatsch ME; Schmidt U; Behnke-Mursch J; Unterberg A; Wirtz CR
Cancer Treat Rev; 2006 Apr; 32(2):74-89. PubMed ID: 16488082
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib: early clinical development in brain cancer.
Addeo R; Zappavigna S; Parlato C; Caraglia M
Expert Opin Investig Drugs; 2014 Jul; 23(7):1027-37. PubMed ID: 24836441
[TBL] [Abstract][Full Text] [Related]
12. Methods of resistance to epidermal growth factor receptor inhibition in glioblastoma multiforme.
Komotar RJ; Starke RM; Connolly ES; Sisti MB
Neurosurgery; 2012 Feb; 70(2):N13-4. PubMed ID: 22251981
[No Abstract] [Full Text] [Related]
13. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo.
Mamot C; Drummond DC; Noble CO; Kallab V; Guo Z; Hong K; Kirpotin DB; Park JW
Cancer Res; 2005 Dec; 65(24):11631-8. PubMed ID: 16357174
[TBL] [Abstract][Full Text] [Related]
14. Antibody Drug Conjugates in Glioblastoma - Is There a Future for Them?
Parakh S; Nicolazzo J; Scott AM; Gan HK
Front Oncol; 2021; 11():718590. PubMed ID: 34926242
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma.
Marin BM; Porath KA; Jain S; Kim M; Conage-Pough JE; Oh JH; Miller CL; Talele S; Kitange GJ; Tian S; Burgenske DM; Mladek AC; Gupta SK; Decker PA; McMinn MH; Stopka SA; Regan MS; He L; Carlson BL; Bakken K; Burns TC; Parney IF; Giannini C; Agar NYR; Eckel-Passow JE; Cochran JR; Elmquist WF; Vaubel RA; White FM; Sarkaria JN
Neuro Oncol; 2021 Dec; 23(12):2042-2053. PubMed ID: 34050676
[TBL] [Abstract][Full Text] [Related]
16. Molecular targeted therapy of glioblastoma.
Le Rhun E; Preusser M; Roth P; Reardon DA; van den Bent M; Wen P; Reifenberger G; Weller M
Cancer Treat Rev; 2019 Nov; 80():101896. PubMed ID: 31541850
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic targeting of EGFR-activated metabolic pathways in glioblastoma.
Gao Q; Lei T; Ye F
Expert Opin Investig Drugs; 2013 Aug; 22(8):1023-40. PubMed ID: 23731170
[TBL] [Abstract][Full Text] [Related]
18. Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumors.
Anami Y; Otani Y; Xiong W; Ha SYY; Yamaguchi A; Rivera-Caraballo KA; Zhang N; An Z; Kaur B; Tsuchikama K
Cell Rep; 2022 May; 39(8):110839. PubMed ID: 35613589
[TBL] [Abstract][Full Text] [Related]
19. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor: a re-emerging target in glioblastoma.
Hegi ME; Rajakannu P; Weller M
Curr Opin Neurol; 2012 Dec; 25(6):774-9. PubMed ID: 23007009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
